Tipifarnib AITL Treatment CXCL12 Biomarker Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer with farnesyltransferase inhibitors (FTIs) face challenges in predicting patient responsiveness and selecting appropriate patients for treatment, leading to variable treatment outcomes in cancers such as angioimmunoblastic T-cell lymphoma (AITL).
Innovation Solution
The use of tipifarnib, a farnesyltransferase inhibitor, is administered to patients with AITL based on specific gene expression patterns, particularly a high CXCL12/CXCR4 expression ratio, determined through analysis of tumor samples, to enhance treatment responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FTI treatment is administered to all cancer patients, then the treatment coverage is maximized, but the response rate varies significantly due to inability to predict patient responsiveness
Solution Approach 1:
The patent applies preliminary action by performing gene expression analysis (detecting CXCL12 and/or CXCR4 expression levels) before administering FTI treatment. This preliminary detection allows clinicians to identify patients who are likely to respond to FTI therapy, thereby improving treatment reliability by selecting appropriate candidates in advance rather than treating all patients uniformly.
2Measurement precision
If gene expression analysis is performed to select patients, then treatment responsiveness is improved, but the diagnostic process becomes more complex
Solution Approach 1:
The patent uses gene expression levels of CXCL12 and/or CXCR4 as intermediary biomarkers to predict patient responsiveness to FTI treatment. These biomarkers serve as measurable intermediaries that correlate with treatment response, allowing clinicians to accurately predict patient outcomes through relatively straightforward molecular detection methods without needing to directly measure complex treatment response parameters.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the field of cancer therapy. Specifically, provided herein is tipifarnib for use in methods of treating an angioimmunoblastic T-cell lymphoma (AITL) in a subject.